AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Healthequity: Raymond James reiterates the 'Strong Buy' Rating, The Target Price is $120
ByAinvest
Tuesday, Jul 8, 2025 2:00 pm ET1min read
Raymond James reiterates 'Strong Buy' rating on Healthequity(HQY).
The target price is $120, compare with $115 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-08 | Raymond James | Reiterates | Strong Buy | Strong Buy | $120 | $115 |
[Recent Earning Results] Healthequity posted the Q1 of its 2025 financial results on 6/3/2025, reporting total revenue of USD 330.84 million in the first quarter, up 15.04% from USD 287.60 million year over year, reporting net income of USD 53.92 million in the first quarter, up 87.12% from USD 28.81 million year over year.
[Company Profile] HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. The company is a leader and an innovator in the high growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. The company's platform provides an ecosystem where consumers can access tax-advantaged health care savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow tax-advantaged health care savings. The company can integrate with any health plan or banking institution to be the independent and trusted partner that enables consumers as seek to manage, save and spend healthcare dollars.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet